Medicus Pharma Ltd. 8-K

What Happened

• Medicus Pharma Ltd. filed an 8-K on March 6, 2026 disclosing that, pursuant to its Standby Equity Purchase Agreement (SEPA) dated February 10, 2025 with YA II PN, Ltd. (Yorkville), it completed multiple unregistered sales of common shares to Yorkville between December 19, 2025 and March 6, 2026.
• In total the Company sold 4,471,038 common shares for aggregate consideration of $3,846,910 (about $0.86 per share on average). The Company used part of the net proceeds to prepay a portion of a debenture it has outstanding with Yorkville.

Key Details

• Total shares sold: 4,471,038; Total proceeds: $3,846,910 (sales occurred Dec 19, 2025–Mar 6, 2026).
• Largest single-date transfers included March 5, 2026 (700,000 and 1,360,000 shares) and March 6, 2026 (1,425,000 shares).
• Sales were issued in reliance on the Section 4(a)(2) exemption from registration; Yorkville may resell the shares under an effective registration statement filed by the Company per the SEPA.
• The Company may cause additional purchases by Yorkville under the SEPA in the future, subject to the agreement’s conditions and limits.

Why It Matters

• These transactions raise the Company’s outstanding share count and can dilute existing shareholders’ ownership.
• The proceeds provided near-term liquidity and were used in part to reduce debt to Yorkville, which affects the company’s capital structure.
• Investors should note the potential for additional share sales under the SEPA and the resale ability by Yorkville once registration is effective, both of which could affect supply of shares in the market.